



Conjugate addition of amines to chiral 3-aziridin-2-yl-acrylates

Doo-Ha Yoon^a, Hyun-Joon Ha^{a,*}, Bong Chan Kim^b, Won Koo Lee^{b,*}

^a Department of Chemistry and Protein Research Centre for Bio-Industry, Hankuk University of Foreign Studies, Yongin 449-719, Republic of Korea

^b Department of Chemistry, Sogang University, Seoul 121-742, Republic of Korea

ARTICLE INFO

Article history:

Received 28 December 2009

Revised 11 February 2010

Accepted 16 February 2010

Available online 19 February 2010

Dedicated with respect to the memory of Professor Chi Sun Hahn

Keywords:

Conjugate addition

Amine

Aziridin-2-yl-acrylates

Diamine

ABSTRACT

Conjugate addition of benzylamine to chiral methyl *cis*-3-aziridin-2-yl-acrylates was successfully proceeded to yield 3-aziridin-2-yl-3-benzylaminopropionates in high yield with high stereoselectivity. The addition products were used for the asymmetric synthesis of vicinal diamine derivatives including 4-amino-5-methylpyrrolidin-2-one, 3,4-diaminopentanoate, and 5-chloromethyl-4-alkoxycarbonylmethylimidazolidin-2-one.

© 2010 Elsevier Ltd. All rights reserved.

Synthesis of stereochemically well-defined 1,2-diamines is still a great challenge to many organic chemists due to their vast utilities as catalysts, metal-ligands, and sub-unit of some natural products.¹ Especially β,γ -diamino acids and their cyclic forms like 4-aminopyrrolidin-2-one and imidazolidin-2-one have unique properties as peptidomimetics² and as constituents of biologically active molecules including renin-inhibitory statin analogs,³ anti-fungal and cytotoxic microsclerodermins,⁴ and antipsychotic nemonapride.⁵ Furthermore, the reduced form of 4-aminopyrrolidin-2-one provides an entry into the 3-aminopyrrolidine family of alkaloids (Fig. 1).⁶

Considering the vast utilities of these compounds, limited methods are available and most of which is based on α -amino acids as starting material through homologations followed by introducing one more amine functionality.⁷ These known methods were suffered from the limited sources of starting substrates and the multi-reaction steps including low yield. In this Letter is described a general and facile synthetic method to access enantiomerically pure anti β,γ -diamino acids and their cyclic forms using chiral aziridine.

During last several years we have shown that enantiomerically pure aziridine-2-carboxylate is a configurationally stable surrogate of α - or β -amino acids.⁸ Homologation and proper functionalization of carboxylate followed by aziridine ring opening provided



Figure 1. β,γ -Diamino acids, 4-aminopyrrolidin-2-ones, and imidazolidine-2-ones.


many valuable compounds such as unnatural amino acids,⁹ sphinganine,¹⁰ phytosphingosine,¹¹ ceramide analogs,¹² and terminal 1,2-diamines.¹³ Homologation by two carbons and introduction of one more amino group adjacent to the aziridine-ring will be able to provide a good synthetic intermediate toward the targeted β,γ -diamino acids and their cyclic forms.

At first *trans*- and *cis*-3-[(1*R*)-phenylethylaziridine]-(2*R*)- and (2*S*)-yl]-acrylates were selectively prepared from aziridine-2-carboxaldehyde.⁸ The reaction of [(1*R*)-phenylethylaziridine]-(2*R*)-carboxaldehyde with $(\text{EtO})_2\text{POCH}_2\text{CO}_2\text{R}$ yielded *trans*-3-[(1*R*)-phenylethylaziridin]-(2*S*)-yl]-acrylate in more than 95% yield with the ratio of 98:2 regardless of R (methyl and ethyl). The same reaction with $\text{Ph}_3\text{PCH}_2\text{CO}_2\text{R}$ leading to alkyl *cis*-3-[(1*R*)-phenylethylaziridin]-(2*R*)- and (2*S*)-yl]-acrylates, **1** and **2**, was also successfully provided in more than 93% yield with the ratio of 88:12 (R = Me) and 86:14 (R = Et). Interestingly, only the *cis* and *trans* isomers bearing methyl ester were chromatographically

* Corresponding authors. Tel.: +82 31 3304369; fax: +82 31 3304566 (H.-J.H.); tel.: +82 2 7058449; fax: +82 2 7010967 (W.K.L.).

E-mail addresses: hjha@hufs.ac.kr (H.-J. Ha), wonkoo@sogang.ac.kr (W.K. Lee).

Table 1
Addition of benzylamines to methyl *cis*-3-[(1*R*)-phenylethylaziridin]-(2*R*)-yl]-acrylate (**1**)




Entry	RNH ₂	Temp (°C)	Time ^a (h)	Yield ^b (%)	Ratio ^c (3A : 3B)
1	PhCH ₂ NH ₂ (a)	rt	14	95	2.9:1
2	PhCH ₂ NH ₂ (a)	0	24	91	2.9:1
3	PhCH ₂ NH ₂ (a)	-40	20	98	4.0:1
4	(<i>R</i>)-Ph(CH ₃)CHNH ₂ (b)	50	7	95	3.3:1
5	(<i>S</i>)-Ph(CH ₃)CHNH ₂ (c)	50	7	97	>99:1

^a The reaction was carried out with amine in MeOH.

^b Yields, not optimized.

^c Ratios, determined by ¹H NMR.




Scheme 1. Reagents and conditions: (i) (1) NaH, Cl₃COCOOCCl₃, -10 °C, THF, 3 h.

separable (*R_f* values, 0.75 and 0.70 for *cis* and *trans*, hexane/EtOAc, 1:1 (v/v)).

Conjugate addition of benzylamine (**a**) to methyl *trans*- and *cis*-3-[(1*R*)-phenylethylaziridin]-(2*R*)-yl]-acrylate in MeOH showed the big difference on the reactivity and stereoselectivity between two substrates. The *cis* isomer **1** is much more reactive to yield the expected diastereomeric mixture **3Aa** and **3Ba** in a 2.9:1 ratio at room temperature while *trans* is quite sluggish with no selectivity (Table 1, entry 1) The ratio obtained of **3Aa** was changed by lowering the reaction temperature to 0 °C and -45 °C as 2.9:1 and 4.0:1, respectively (Table 1, entries 2 and 3). Addition of chiral amines for the possible improvement of diastereoselectivity was succeeded with (*R*)- and (*S*)- α -methylbenzylamine (**b** and **c**) to yield addition products. In case of (*R*)- α -methylbenzylamine (**b**) not much improvement was observed in terms of selectivity to give 3.3:1 (**3Ab**:**3Bb**) (entry 4). However, the addition of (*S*)- α -methylbenzylamine (**c**) yielded a single isomer **3Ac** as a sole product judged by NMR and HPLC analyses (entry 5). This high selectivity arisen from the right match between 2*R* configuration

Table 2
Addition of benzylamines to methyl *cis*-3-[(1*R*)-phenylethylaziridin]-(2*S*)-yl]-acrylate (**2**)



Entry	RNH ₂	Temp (°C)	Time ^a (h)	Yield ^b (%)	Ratio ^c (4A : 4B)
1	PhCH ₂ NH ₂ (a)	rt	14	96	2.3:1
2	PhCH ₂ NH ₂ (a)	0	24	91	2.3:1
3	PhCH ₂ NH ₂ (a)	-40	30	95	2.6:1
4	(<i>R</i>)-Ph(CH ₃)CHNH ₂ (b)	50	8	82	1.2:1
5	(<i>S</i>)-Ph(CH ₃)CHNH ₂ (c)	50	8	95	2.1:1

^a The reaction was carried out with amine in MeOH.

^b Yields, not optimized.

^c Ratios, determined by ¹H NMR.

of the phenylethyl group of the aziridine ring and (*S*)- α -methylbenzylamine nucleophile.

The inseparable diastereomeric mixture of **3Aa** and **3Ba** obtained from entry 2 in Table 1 was further reacted with triphosgene and NaH to yield 4-chloromethyl-5-methoxycarbonylmethylimidazolidin-2-ones **5** and **6** (Scheme 1).¹⁴

The coupling constants of two vicinal hydrogens at C4 and C5 of compounds **5** (major) and **6** (minor) were 7.5 and 3.0 Hz, respectively. On the basis of these values we could determine the stereochemistry of **3Aa** and **3Ba** as *erythro* and *threo*, respectively.^{14,15}

A similar selectivity was observed with methyl *cis*-3-[(1*R*)-phenylethylaziridin]-(2*S*)-yl]-acrylate (**2**) as the starting substrate and benzylamine (**a**) to give a *erythro* (**4Aa**) and *threo* (**4Ba**) mixture with the ratio as 2.3:1 and 2.6:1 (entries 1–3 of Table 2). Both the chiral nucleophiles (*R*)- α -methylbenzylamine (**b**) and (*S*)- α -methylbenzylamine (**c**) with **2** yielded addition products with poor selectivities as 1.2:1 and 2.1:1, respectively (entries 4 and 5 of Table 2).

The drastic difference in the stereoselectivity was observed during the addition reaction of the chiral nucleophiles (*R*)- α -methylbenzylamine (**b**) and (*S*)- α -methylbenzylamine (**c**) to either **1** or **2** (entries 4 and 5 in Table 1 and Table 2). This implies the participation of the α -methylbenzyl group at the ring nitrogen and the coming nucleophile resulted the 'matched' (entry 5 in Table 1) and 'mismatched' cases (entry 4 in Table 1, and entries 4 and 5 in Table 2) in the transition state during the course of the reaction.¹⁶

The possible transition state stems from the most stable conformer of 2-substituted aziridine with two substituents X and Y





Figure 2. (a), (b) Front and side views of the aziridine with two substituents X and Y at N1 and C2. (c) View of methyl *cis*-3-[(1'*R*)-phenylethylaziridin]-(2*R*)-yl-acrylate (**1**) and the possible approaching faces of the amine nucleophile in the transition state model.



Scheme 2. Reagents and conditions: (i) (1) H_2 (1 atm), $Pd(OH)_2$, rt, 4 h, (2) $(Boc)_2O$, MeOH, rt, two steps 89%. (ii) LiOH, EtOH/ H_2O = 5:1 (v/v) 50 °C, 8 h, rt, ion-exchange column, 82%.

situated in *trans*-relationships as shown in Figure 2 (a) and (b). This *trans*-relationship was also observed in many crystalline structures of aziridines.¹⁷ Putting both substituents of phenylethyl (X) and methoxycarbonylphenyl (Y) groups generates the structure (c) in Figure 2 with possible two faces, *re* and *si*, for the nucleophile to come.

Among two possible directions *re* face attack is more favorable rather than *si* face away from the steric hindrance, which is the controlling factor to yield the *erythro* adduct as the major product along with the additional stereodifferentiation by (*R*)- α -methylbenzylamine. This stereochemical pathway is opposite to the reaction with chelation-controlled transition state to yield the *threo* product.¹⁴

The addition product **3Ac** was further treated with an atmospheric pressure of hydrogen in the presence of $Pd(OH)_2$ catalyst followed by reaction with $(Boc)_2O$ to yield (4*R*,5*S*)-4-*t*-butyloxycarbonylamino-5-methylpyrrolidin-2-one (**7**) in a 89% yield. Hydrolysis of **7** followed by anion exchange column afforded the known (3*R*,4*S*)-4-amino-3-*t*-butyloxycarbonylaminopentanoic acid (**8**) in a 82% yield (Scheme 2).¹⁸ The addition product **3Ac** will be served as a synthetic intermediate for the preparation of various chiral diamines through aziridine ring opening with various nucleophiles.⁸

In conclusion, the conjugate addition of benzylamine to chiral methyl *cis*-3-[(1'*R*)-phenylethyl-aziridin]-(2*R*)- and (2*S*)-yl-acrylates provides the *erythro* adduct, 3-(aziridin-2-yl)-3-benzylamino-propionate as the major product. Additional stereodifferentiation by (*S*)- α -methylbenzylamine to the substrate (2*R*)-acrylates yielded a single enantiomeric adduct in high yield which was used as the precursor for the substituted nitrogen-containing heterocycles and enantiomerically pure β,γ -diaminoacids.

Acknowledgments

This work was supported by the Hufs Grant (2010) and Korea Science and Engineering Foundation (R01-2007-000-20037-0 for H.-J.H and KRF-2008-C00481 and NRF-2009-0081956 for W.K.L.).

Supplementary data

Supplementary data (experimental procedures and characterization data for all new compounds) associated with this article can be found, in the online version, at doi:10.1016/j.tetlet.2010.02.087.

References and notes

- For reviews on the chemistry of 1,2-diamines, see: (a) Kotti, S. R. S. S.; Timmons, C.; Li, G. *Chem. Biol. Drug. Design.* **2006**, *67*, 101; (b) Fache, F.; Schulz, E.; Tommasino, M. L.; Lemaire, M. *Chem. Rev.* **2000**, *100*, 2159; (c) Lucet, D.; Le Gall, T.; Mioskowski, C. *Angew. Chem., Int. Ed.* **1998**, *37*, 2580.
- (a) Hoang, C. T.; Alezra, V.; Guillot, R.; Kouklovsky, C. *Org. Lett.* **2007**, *9*, 2521; (b) Lehmann, T.; Michel, D.; Glänzel, M.; Waibel, R.; Gmeiner, P. *Heterocycles* **1999**, *51*, 1389.
- Jones, D. M.; Sueiras-Diaz, J.; Szelke, M.; Leckie, B. J.; Beattie, S. R.; Morton, J.; Neidle, S.; Kuroda, R. *J. Pept. Res.* **1997**, *50*, 109.
- (a) Skropeta, D. *Nat. Prod. Rep.* **2008**, *25*, 1131; (b) Hoang, C. T.; Nguyen, V. H.; Alezra, V.; Kouklovsky, C. *J. Org. Chem.* **2008**, *73*, 1162; (c) Bewley, C. A.; Debitus, C.; Faulkner, D. J. *J. Am. Chem. Soc.* **1994**, *116*, 7631.
- Iwanami, S.; Takashima, M.; Hirata, Y.; Hasegawa, O.; Usuda, S. *J. Med. Chem.* **1981**, *24*, 1224.
- For more recent examples, see: (a) Jin, J.; An, M.; Sapienza, A.; Aiyar, N.; Naselsky, D.; Sarau, H. M.; Foley, J. J.; Salyers, K. L.; Knight, S. D.; Keenan, R. M.; Rivero, R. A.; Dhanak, D.; Douglas, S. A. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 3950; (b) Fish, P. V.; Barta, N. S.; Gray, D. L. F.; Ryckmans, T.; Stobie, A.; Wakenhut, F.; Whitlock, G. A. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 4355; (c) Wakenhut, F.; Fish, P. V.; Fray, M. J.; Gurrell, I.; Mills, J. E.; Stobie, A.; Whitlock, G. A. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 4308.
- (a) Pinheiro, S.; da Silva Júnior, R. C.; de Souza, A. S.; de M Carneiro, J. W.; Muri, E. M. F.; Antunes, O. A. C. *Tetrahedron. Lett.* **2009**, *50*, 2402; (b) Hoang, C. T.; Bouillere, F.; Johannesen, S.; Zulauf, A.; Panel, C.; Pouilhes, A.; Gori, D.; Alezra, V.; Kouklovsky, C. *J. Org. Chem.* **2009**, *74*, 4177. and references cited therein.
- Lee, W.-K.; Ha, H.-J. *Aldrichimica Acta* **2003**, *36*, 57, and references cited therein.
- Park, C. S.; Choi, H. G.; Lee, H.; Lee, W. K.; Ha, H.-J. *Tetrahedron: Asymmetry* **2000**, *11*, 3283.
- Yun, J. M.; Sim, T. B.; Hahm, H. S.; Lee, W. K.; Ha, H.-J. *J. Org. Chem.* **2003**, *68*, 7675.
- Yoon, H. J.; Kim, Y.-W.; Lee, B. K.; Lee, W. K.; Kim, Y.; Ha, H.-J. *Chem. Commun.* **2007**, 79.
- Ha, H.-J.; Hong, M. C.; Ko, S. W.; Kim, Y. W.; Lee, W. K.; Park, J. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 1880.
- Lee, B. K.; Kim, M. S.; Hahm, H. S.; Kim, D. S.; Lee, W. K.; Ha, H.-J. *Tetrahedron* **2006**, *62*, 8393.
- Suh, M.-J.; Kim, S. W.; Beak, S. I.; Ha, H.-J.; Lee, W.-K. *Synlett* **2004**, 489.
- (a) Pelletier, S. M.-C.; Ray, P. C.; Dixon, D. *J. Org. Lett.* **2009**, *11*, 4512; (b) Park, C. S.; Kim, M. S.; Sim, T. B.; Pyun, D. K.; Lee, C. H.; Choi, D.; Lee, W. K.; Chang, J.-W.; Ha, H.-J. *J. Org. Chem.* **2003**, *68*, 43.
- In our early work we observed that the configuration of (α)-methylbenzyl group at N1 of aziridine affected drastically the reactivity on the substitution reaction of 2-sulfonyloxymethylaziridines. Han, S.-M.; Ma, S.-h.; Ha, H.-J.; Lee, W. K. *Tetrahedron* **2008**, *64*, 11110.
- (a) Lee, K.-D.; Suh, J.-M.; Park, J.-H.; Ha, H.-J.; Choi, W. G.; Park, C. S.; Chang, J. W.; Lee, W. K.; Dong, Y.; Yun, H. *Tetrahedron* **2001**, *57*, 8267; (b) Dong, Y.; Yun, H.; Park, C. S.; Lee, W.-K.; Ha, H.-J. *Acta Crystallogr., Sect. C* **2003**, *59*, 659.
- Kano, S.; Yokomatsu, T.; Iwasawa, H.; Shibuya, S. *Chem. Pharm. Bull.* **1988**, *36*, 3341.